logo
Unpasteurized vs. pasteurized: What to know about food safety

Unpasteurized vs. pasteurized: What to know about food safety

The Hill6 days ago
A long-practiced food processing method has been up for debate in recent years, with some opting to drink and eat without sterilizing it first.
The polarizing process is pasteurization — a heating process that kills the microbes behind common foodborne illnesses.
Prominent pushes for 'raw milk' consumption are growing, whether it's Health and Human Services Secretary Robert F. Kennedy Jr. or Gwyneth Paltrow.
While still on the 2024 campaign trail for his failed presidential bid, Kennedy said he only drinks unpasteurized milk. In April, he suspended a quality control program for testing the nation's dairy supply.
All the while, experts and researchers are advocating for Americans to only consume pasteurized milk.
Pasteurized vs unpasteurized: What's the difference?
Pasteurization is the process of heating a food product for a certain amount of time to destroy bacteria and viruses present, according to the Centers for Disease Control and Prevention (CDC).
Dairy products, eggs, juices, canned food, flour, honey and alcohol, among others, are typically pasteurized.
Unpasteurized products don't undergo the heating and germ-killing process. They can include milk, artisanal cheese, juice, meat and more.
Benefits, drawbacks of pasteurization
By getting rid of harmful microbes, pasteurization can prevent foodborne illnesses like listeriosis, typhoid fever, tuberculosis, diphtheria, Q fever, and brucellosis, according to the Food and Drug Administration (FDA).
Pasteurization can also change the nutritional value, flavor and appearance of food, though only minimally, per the National Library of Medicine.
'Pasteurized milk offers the same nutritional benefits without the risks of raw milk consumption. Since the early 1900s, pasteurization has greatly reduced milk-borne illnesses,' the CDC says.
Are unpasteurized foods safe? What are the risks?
Some believe that so-called 'raw milk' and other unpasteurized products are a healthier option, since they are straight from nature.
Some champion positive health returns from drinking unpasteurized milk, including raw milk farmer Cliff McConville: 'I can tell you that I used to get sick like three times a year, like, you know, with colds or flu, and I almost never get sick anymore.'
But most medical bodies and independent experts say the benefits of unpasteurized food don't outweigh the potential health problems.
The CDC and the FDA have warned that raw milk is unsafe because bacteria in it can cause illness or even death.
The bird flu virus can remain infectious in raw milk for over a day at room temperature and more than a week when refrigerated, according to a non-peer-reviewed study from a group of UK scientists.
The study, published in medRxiv, examined the stability of the H5N1 avian influenza virus in raw cow and sheep milk, with researchers simulating storage conditions common in dairy settings.
'High viral titres were detected in milk from infected cows, raising concerns about onwards human infections,' the authors wrote.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Are RSV Vaccine Rates so Shockingly Low?
Why Are RSV Vaccine Rates so Shockingly Low?

Medscape

time9 minutes ago

  • Medscape

Why Are RSV Vaccine Rates so Shockingly Low?

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and children younger than 2 years. The most severe and life-threatening cases typically affect infants younger than 6 months. However, older toddlers, adults with chronic illnesses or multiple comorbidities, and older adults are also at an elevated risk. Immunization Progress Research on both active and passive RSV immunization has advanced significantly in recent years. Following the approval of the first prophylactic antibody in 2022 and two vaccines in 2023, the prevention of severe RSV illnesses has become increasingly effective. Current strategies include maternal vaccination to protect newborns, immunization of older adults, and passive immunization of infants using the monoclonal antibody nirsevimab. In June, the FDA approved a second monoclonal antibody: clesrovimab. Nirsevimab Nirsevimab (Beyfortus) has been available in the European Union since November 2022. It is indicated for RSV prophylaxis in all infants during their first RSV season and in children up to 2 years of age who are at increased risk during their second season. Nirsevimab is a human monoclonal immunoglobulin G1 (IgG1) kappa antibody produced using recombinant DNA technology. It binds to a highly conserved site on the RSV fusion (F) glycoprotein, which is present only in the prefusion form of the viral surface protein. Nirsevimab has a markedly longer serum half-life than earlier antibodies. The drug is administered as a single intramuscular dose adjusted according to the child's weight. Germany's Standing Committee on Vaccination recommends that infants born between April and September receive antibodies in autumn before their first RSV season. Those born between October and March should receive the vaccine as soon as possible after birth. Clesrovimab Clesrovimab (Enflonsia) is a human monoclonal IgG1 kappa antibody. Unlike nirsevimab, it binds to two sites in both the pre- and post-fusion conformations of the F protein. It is administered as a single intramuscular injection and does not require weight-based dosing. The manufacturer has applied for approval from the European Medicines Agency, and the decision is pending. RSV Vaccines Three RSV vaccines, each targeting a different group, are currently authorized for use in Germany. Arexvy: A monovalent recombinant protein vaccine that includes the RSV F protein and the AS01E adjuvant. It is approved for adults aged 60 years or older. Abrysvo: A bivalent recombinant protein vaccine containing prefusion F antigens from RSV subtypes A and B. It is authorized for use in pregnant women to protect their infants up to 6 months of age and in adults aged 60 years or older. mResvia: Approved in mid-2024, this is the only mRNA RSV vaccine currently available. It is indicated for adults aged 60 years or older and was recently approved in the US for high-risk adults aged 18-59 years. Real-World Data Although clinical trials have demonstrated the strong efficacy of RSV vaccines and antibodies in preventing severe illnesses, data from real-world immunization programs are limited. A new systematic review by UK researchers addressed this gap. Between December 2024 and February 2025, they conducted monthly searches across the Ovid, Embase, MEDLINE, and global health databases. The review included 43 studies that evaluated nirsevimab, maternal RSV vaccination, and adult RSV vaccination. The goal was to assess uptake across countries and demographic groups. Data from more than 1.38 million individuals in Spain, France, Italy, Luxembourg, and the US were analyzed. One study combined records from Catalonia and Andorra. Most data (86%) were drawn from electronic health records and medical registries, and vaccine data were solely from the US. Nirsevimab Uptake In Spain, the uptake of nirsevimab during the 2023-2024 RSV season reached 90.1% (95% CI, 86.4-92.9), the highest of any country reviewed. Infants born during the RSV season and Spanish nationals had higher immunization rates. In the US, 51.2% of eligible infants received nirsevimab in 2023-2024. Uptake was greater among preterm infants, those with at least one comorbidity, and those from Hispanic backgrounds. France recorded 76.5% coverage, with higher rates in infants younger than 3 months than in those aged 3-12 months. Luxembourg reported 83.8%, Italy 68.7%, and Catalonia-Andorra combined 60.2%. Subgroup analyses revealed that children who experienced RSV or other acute respiratory infections were less likely to receive nirsevimab. Maternal Vaccination Maternal RSV vaccine coverage during pregnancy was 30.5% (95% CI, 20.6-42.6). Uptake was significantly lower among women without health insurance or with statutory coverage than among those with private insurance. Black and Hispanic women had lower rates than non-Hispanic White women. Older Adult Vaccination Four population-based studies assessed RSV vaccine uptake in adults aged 60 years or older, showing an average rate of 18.2% (95% CI, 10.8-28.9) in 2023-2024. Uptake was higher among adults older than 75 years, those with comorbidities, and immunocompromised individuals. As with maternal vaccination, the rates were lower among the Black and Hispanic populations. The researchers highlighted the concerningly low uptake among pregnant women and older adults despite the availability of effective prevention tools. They called for coordinated national, clinical, and public health efforts to improve immunization rates in high-risk populations. World Health Organization (WHO) Guidance In May, the WHO published its first position paper on RSV immunization in infants and young children, underscoring global urgency. RSV is the leading cause of pediatric morbidity and mortality. In 2019, an estimated 100,000 children younger than 5 years died from RSV-related lower respiratory tract infections, representing about 2% of all deaths in this age group. Approximately half of these deaths occur in infants younger than 5 months, with 97% occurring in low- and middle-income countries. Globally, RSV accounts for an estimated 3.6 million hospitalizations annually in children younger than 5 years. The WHO recommends that all countries implement immunization programs to prevent severe RSV disease in vulnerable groups. The choice between maternal vaccination and the use of long-acting monoclonal antibodies, such as nirsevimab, should be based on local factors, including health system integration, cost, and overall feasibility. Germany's Robert Koch Institute provides additional guidance in its fact sheets on RSV immunization, including details on nirsevimab and adult vaccinations.

NextCure presents new preclinical data on osteogenesis imperfecta treatment
NextCure presents new preclinical data on osteogenesis imperfecta treatment

Business Insider

time2 hours ago

  • Business Insider

NextCure presents new preclinical data on osteogenesis imperfecta treatment

NextCure (NXTC) announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. The data were presented at the Brittle Bone Society Meeting on July 24th, 2025. These results demonstrate that NC605 could be a highly effective treatment for OI, also known as brittle bone disease. OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 has been shown to inhibit bone loss and to produce new bone, with increased quality and density. Fracture incidence and bone architecture were assessed in male and female OI mice treated with weekly 20 mg/kg of surrogate antibody NP159 and compared to control groups treated with twice weekly 50 mg/kg anti-sclerostin or saline. NP159 increased cortical and trabecular bone mineral density, tissue mineral density, cortical thickness and decreased trabecular separation compared to saline-treated mice. 'In a mouse model of moderate-to-severe OI, NP159, a surrogate murine antibody for NC605, improved trabecular and cortical bone density and reduced fracture incidence comparable to anti-sclerostin,' said Priyanka Kothari, Ph.D., NextCure's Director, Translational Research. 'There is currently no standard of care approved by the FDA for patients with OI and NC605 has the potential to provide significant therapeutic benefit for patients.'

Planned Parenthood closes 5 Northern California clinics, citing Trump budget bill
Planned Parenthood closes 5 Northern California clinics, citing Trump budget bill

San Francisco Chronicle​

time4 hours ago

  • San Francisco Chronicle​

Planned Parenthood closes 5 Northern California clinics, citing Trump budget bill

President Donald Trump's budget cuts to Medicaid have forced Planned Parenthood Mar Monte to shutter five clinics across Northern California and the Central Coast, including one in South San Francisco, the group said Thursday. The GOP-led federal spending bill that Trump signed into law earlier this month eliminated federal Medicaid funding for any type of medical care to organizations that perform abortions. Mar Monte is the largest Planned Parenthood affiliate in the country, with health care centers from Bakersfield, the Bay Area, Stockton and Sacramento. The now-shuttered facilities also include San Mateo, Santa Cruz, Gilroy and Madera. The closures represent the first wave of how the recent federal budget cuts will have real-life consequences for health clinics across the country — particularly for low-income Americans. They are also a crushing blow to a state that set it up to be an abortion haven after the U.S. Supreme Court overturned Roe v. Wade in 2022. In the year after the decision, political leaders in California — led by Gov. Gavin Newsom and the Democratic-controlled Legislature — passed more than a dozen new laws and invested more than $200 million to increase access across the state. Thursday's announcement drives home the extent of the federal government's tremendous power to impact abortion access. Roughly 80% of Mar Monte's patients received Medi-Cal, California's version of Medicaid. Ten million people are expected to lose their health insurance because of nearly $1 trillion in Medicaid cuts over the next decade in the One Big Beautiful Bill Act, according to the nonpartisan Congressional Budget Office. Meanwhile, the wealthiest Americans will receive a disproportionate share of the tax cuts funded by those cuts, according to the Center for Budget and Policy Priorities. In just one week since Mar Monte stopped billing Medicaid, the Planned Parenthood affiliate with 35 locations said it saw 5,000 patients — amounting to about $1.7 million in care costs it covered without reimbursement — Mar Monte Chief of Staff Andrew Adams told the Chronicle Thursday. 'It's just not sustainable,' said Adams. 'We can't keep our doors open if we continue doing that.' Mar Monte said the funding law also forced it to end services in family medicine, behavioral health and prenatal care. The Planned Parenthood affiliate estimates it will lose $100 million in annual revenue from care that can no longer be reimbursed under the law because they provide abortion care. Americans tend to support abortion rights, according to public polling. A May 2025 Gallup Poll found that 51% of respondents described themselves as 'pro choice' while 43% described themselves as 'pro life.'Of those respondents who said they were 'dissatisfied' with the nation's abortion polices, 42% said they would like to see them made 'less strict' while 14% wanted them to be 'stricter.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store